Press Release: Viz.ai Closes 2025 with Record Scale and Patient Impact Achieving Profitability in Its Healthcare Business while Accelerating Life Sciences Growth

Contact Us
Providers

Viz.ai One
Viz One: Enterprise Platform

Viz Assist
Viz Assist: Workflow Assistant

Viz Neuro Suite
Cerebral Aneurysm
CT Perfusion (CTP)
Hemorrhage
Hyperdensity Measurements
Large Vessel Occlusion (LVO)
Post Acute Stroke

Viz Vascular Suite
Aortic Disease
Pulmonary Embolism

Viz Cardio Suite
Hypertrophic Cardiomyopathy
Post Acute Stroke
Acute Coronary Syndrome (ACS)

Viz Oncology Suite
Viz Oncology

Viz Trauma Suite
Viz Trauma

Viz Radiology Suite
Viz.ai and Microsoft Cloud for Healthcare

Pilot Programs
Oncology
Cardiology
Respiratory
Neurology
Osteoporosis
Life Sciences

Life Sciences

Discover how we work with life sciences partners to drive patient care innovation.

Go to Life Sciences
Customers

Support

Help Center

Customer Resources

User Guides (EU only)

Viz Academy
Clinical Research

Publications

HCM Education Series
Resources

All Resources

Webinars

Events
Brochures

Brochures
Case Studies

Case Studies
Clinical Validation

Clinical Validation

Press & News

Blog

White papers
Podcasts

Podcasts
video

Videos
shield check

Trust Center
About Us

Our Story

Leadership

Careers
Contact Us
Home / Publications / Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection
Viz HCM

Clinical implementation of an AI-enabled ECG for hypertrophic cardiomyopathy detection

In an open-label, multicentre prospective cohort study, Viz HCM (Viz.ai)—an AI-ECG software alerting of suspected HCM—was implemented at five healthcare systems between January and December 2023 to identify patients >18 years of age without prior HCM diagnosis.

Researcher:

Lampert et al.

Published:

Apr 16, 2025

View publication